Pharmacodynamic effects of dasatinib on the Src pathway. Aaron J. Scott Eun-Kee Song Stacey Bagby Alicia Purkey Martin McCarter Csaba Gajdos Kevin S. Quackenbush Benjamin Cross Todd M. Pitts Aik Choon Tan S. Gail Eckhardt Hubert Fenton John Arcaroli Wells A. Messersmith 10.1371/journal.pone.0187173.g004 https://plos.figshare.com/articles/figure/Pharmacodynamic_effects_of_dasatinib_on_the_Src_pathway_/5560561 <p>A) Treatment with dasatinib (0.8 μmol/L) at 0.5h, 1h, 2h, 4h, and 8h significantly reduced the activation of Src, FAK and paxillin at all time points examined in the HCT116 sensitive CRC cell line when compared to control. B) A decrease in Src activity was seen in 1 out of 3 CRC explants treated with dasatinib in the sensitive (CRC036) and resistant CRC explant (CRC027) measured at end of study (day 28). However, in both cases FAK activity appeared to be increased.</p> 2017-11-01 17:38:02 Src pathway anti-proliferative activity 72 hours 17 CRC explants Src expression dasatinib treatment CRC explants G 1 inhibition baseline increase anti-tumor effects Methods CRC cell lines 50 CRC cell lines tumor growth inhibition anti-invasive activity vivo efficacy G 1 cell cycle arrest sulforhodamine B explant mouse model Background Dysregulation FAK gene expression 17 patient-derived CRC explants SRB xenograft mouse model anti-tumor activity PDX patient-derived tumor explant Conclusion Dasatinib CRC cell lines TGI colorectal cancer cell lines IC 28 days